{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:02:34Z","timestamp":1791442954143,"version":"4.3.3"},"reference-count":37,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scoring systems aim to select patients for transplantation. Here, we aimed to develop a prognostic score to determine prognosis after transplantation itself, using clinical, molecular, and transplant-specific information from a total of 361 patients with myelofibrosis. Of these, 205 patients were used as a training cohort to create a clinical-molecular myelofibrosis transplant scoring system (MTSS), which was then externally validated in a cohort of 156 patients. Multivariable analysis on survival identified age at least 57 years, Karnofsky performance status lower than 90%, platelet count lower than 150 \u00d7 109\/L, leukocyte count higher than 25 \u00d7 109\/L before transplantation, HLA-mismatched unrelated donor, ASXL1 mutation, and non-CALR\/MPL driver mutation genotype being independent predictors of outcome. The uncorrected concordance index for the final survival model was 0.723, and bias-corrected indices were similar. Risk factors were incorporated into a 4-level MTSS: low (score, 0-2), intermediate (score, 3-4), high (score, 5), and very high (score, &amp;gt;5). The 5-year survival according to risk groups in the validation cohort was 83% (95% confidence interval [CI], 71%-95%), 64% (95% CI, 53%-75%), 37% (95% CI, 17%-57%), and 22% (95% CI, 4%-39%), respectively (P &amp;lt; .001). Increasing score was predictive of nonrelapse mortality (P &amp;lt; .001) and remained applicable to primary (0.718) and post-essential thrombocythemia (ET)\/polycythemia vera (PV) myelofibrosis (0.701) improving prognostic ability in comparison with all currently available disease-specific systems. In conclusion, this MTSS predicts outcome of patients with primary and post-ET\/PV myelofibrosis undergoing allogeneic stem cell transplantation.<\/jats:p>","DOI":"10.1182\/blood-2018-12-890889","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T20:16:33Z","timestamp":1550088993000},"page":"2233-2242","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":179,"title":["Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation"],"prefix":"10.1182","volume":"133","author":[{"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ditschkowski","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashit","family":"Bogdanov","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swann","family":"Bredin","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie-Greffe and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie-Greffe and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-3905","authenticated-orcid":false,"given":"Bruno","family":"Cassinat","sequence":"additional","affiliation":[{"name":"Laboratoire de biologie cellulaire, H\u00f4pital Saint-Louis, Assistance Publique H\u00f4pitaux de Paris, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Shahswar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie-Greffe and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Triviai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Badbaran","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021108582186200_B1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2017.1.489","article-title":"Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond","volume":"2017","author":"Harrison","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2020021108582186200_B2","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020021108582186200_B3","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/leu.2014.220","article-title":"Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?","volume":"28","author":"Barosi","year":"2014","journal-title":"Leukemia"},{"issue":"13","key":"2020021108582186200_B4","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2020021108582186200_B5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020021108582186200_B6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021108582186200_B7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2020021108582186200_B8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2020021108582186200_B9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"4","key":"2020021108582186200_B10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020021108582186200_B11","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021108582186200_B12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"2020021108582186200_B13","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"2020021108582186200_B14","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2020021108582186200_B15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbmt.2017.09.016","article-title":"Hematopoietic cell transplantation for myelofibrosis: the Dynamic International Prognostic Scoring System plus risk predicts post-transplant outcomes","volume":"24","author":"Samuelson Bannow","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020021108582186200_B16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020021108582186200_B17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"2020021108582186200_B18","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2020021108582186200_B19","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2020021108582186200_B20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2020021108582186200_B21","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2020021108582186200_B22","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"2020021108582186200_B23","volume-title":"ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","author":"Shaffer","year":"2009"},{"key":"2020021108582186200_B24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc [Ser B]"},{"issue":"282","key":"2020021108582186200_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"2020021108582186200_B26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"issue":"446","key":"2020021108582186200_B27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"2020021108582186200_B28","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"25","key":"2020021108582186200_B29","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2020021108582186200_B30","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021108582186200_B31","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3324\/haematol.2011.061168","article-title":"Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Ditschkowski","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"2020021108582186200_B32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ajh.25053","article-title":"Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"2020021108582186200_B33","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2020021108582186200_B34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbmt.2017.10.037","article-title":"Transplant decisions in patients with myelofibrosis: should mutations be the judge?","volume":"24","author":"Salit","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2020021108582186200_B35","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"2020021108582186200_B36","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.28857","article-title":"Comorbidities predict worse prognosis in patients with primary myelofibrosis","volume":"120","author":"Newberry","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"2020021108582186200_B37","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/20\/2233\/1557237\/blood890889.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/20\/2233\/1557237\/blood890889.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T15:37:12Z","timestamp":1720971432000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/20\/2233\/273841\/Comprehensive-clinicalmolecular-transplant-scoring"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":37,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,5,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-12-890889","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735094543.793564963","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]}}}